Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05179889 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Mar 15, 2025 to Jul 5, 2028
    • Trial status: Enrolling by Invitation to Recruiting
    • Study completion date: Mar 15, 2028 to Mar 15, 2031
    • Site details revised
    v3
  2. Trial status: Recruiting to Enrolling by Invitationv2 Show 4 more changesShow less
    • Interventions: FOLFOXIRI (Drug), mFOLFOX 6 (Drug) to mFOLFIRINOX (Drug), mFOLFOX 6 (Drug)
    • Study description revised
    • Site details revised
    • Study title revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A multicenter, open labeled randomized, phase II trial comparing mFOLFIRINOX and mFOLFOX6 as adjuvant treatment for high risk stage III (pT4N1/2 or pTanyN2) colon cancer
Trial Details
NCT Number NCT05179889
Lead Sponsor Chungnam National University Hospital
Collaborators: Boryung Pharmaceutical Co., Ltd
Conditions
(from sponsor)		 Colon Cancer Stage III
Related terms Colonic Neoplasms
Enrollment 308 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov